Adaptimmune Therapeutics Cash from Financing (TTM) Insights

Adaptimmune Therapeutics PLC (ADAP)

1.02 -0.04 (-3.77%) USD | NASDAQ | Apr 16, 14:04

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2016. Upgrade now.

Date	Value
December 31, 2023	0.88M
September 30, 2023	2.209M
June 30, 2023	3.065M
March 31, 2023	13.03M
December 31, 2022	12.87M
September 30, 2022	11.52M
June 30, 2022	10.20M
March 31, 2022	2.789M
December 31, 2021	3.288M
September 30, 2021	3.358M
June 30, 2021	3.685M
March 31, 2021	249.14M
December 31, 2020	340.05M
September 30, 2020	339.93M
June 30, 2020	339.46M
March 31, 2020	91.77M

Date	Value
December 31, 2019	0.366M
September 30, 2019	0.47M
June 30, 2019	100.63M
March 31, 2019	101.19M
December 31, 2018	102.69M
September 30, 2018	102.59M
June 30, 2018	2.794M
March 31, 2018	43.70M
December 31, 2017	103.57M
September 30, 2017	103.58M
June 30, 2017	103.22M
March 31, 2017	61.41M
December 31, 2016	0.017M
September 30, 2016	0.00
June 30, 2016	-4.093M
March 31, 2016	94.25M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

0.366M

Minimum

Dec 2019

340.05M

Maximum

Dec 2020

80.46M

Average

10.20M

Median

Jun 2022

Cash from Financing (TTM) Benchmarks